The impact of phyto- and endo-cannabinoids on central nervous system diseases: A review

Background and aim: Cannabis sativa L. is a medicinal plant with a long history. Phyto-cannabinoids are a class of compounds from C. sativa L. with varieties of structures. Endocannabinoids exist in the human body. This article provides an overview of natural cannabinoids (phyto-cannabinoids and endocannabinoids) with an emphasis on their pharmacology activities. Experimental procedure: The keywords "Cannabis sativa L", "cannabinoids", and "central nervous system (CNS) diseases" were used for searching and collecting pieces of literature from PubMed, ScienceDirect, Web of Science, and Google Scholar. The data were extracted and analyzed to explore the effects of cannabinoids on CNS diseases. Result and conclusion: In this paper, schematic diagrams are used to intuitively show the phytocannabinoids skeletons' mutual conversion and pharmacological activities, with special emphasis on their relevant pharmacological activities on central nervous system (CNS) diseases. It was found that the endocannabinoid system and microglia play a crucial role in the treatment of CNS diseases. In the past few years, pharmacological studies focused on Δ^9-THC, CBD, and the endocannabinoids system. It is expected to encourage new studies on a more deep exploration of other types of cannabinoids and the mechanism of their pharmacological activities in the future.

關鍵字

Cannabinoids ； Chemical structures ； Endocannabinoid system ； CNS diseases

參考文獻

Aymerich MS, Aso E, Abellanas MA, et al. Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system. Biochem Pharmacol. 2018;157:67-84. https://doi.org/10.1016/j.bcp.2018.08.016

Van Den Elsen GAH, Tobben L, Ahmed AIA, et al. Effects of tetrahydrocan-nabinol on balance and gait in patients with dementia: a randomized controlled crossover trial. J Psychopharmacol. 2017;31(2):184-191. https://doi.org/10.1177/0269881116665357

Solas M, Francis PT, Franco R, Ramirez MJ. CB2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients. Neurobiol Aging. 2013;34(3): 805-808. https://doi.org/10.1016/j.neurobiolaging.2012.06.005

Sveinbjornsdottir S. The clinical symptoms of Parkinson's disease. J Neurochem. 2016;139:318-324. https://doi.org/10.1111/jnc.13691

Duffy SS, Hayes JP, Fiore NT, Moalem-Taylor G. The cannabinoid system and microglia in health and disease. Neuropharmacology. 2021;190, 108555. https://doi.org/10.1016/j.neuropharm.2021.108555

延伸閱讀

Vuolo, F., Petronilho, F., Sonai, B., Ritter, C., Hallak, J. E. C., Zuardi, A. W., Crippa, J. A., & Pizzol, F. D. (2015). Evaluation of Serum Cytokines Levels and the Role of Cannabidiol Treatment in Animal Model of Asthma. Mediators of Inflammation, 2015(), 821-825-273. https://doi.org/10.1155/2015/538670
Capettini, L. S. A., Savergnini, S. Q., Silva, R. F. D., Stergiopulos, N., Santos, R. A. S., Mach, F., & Montecucco, F. (2012). Update on the Role of Cannabinoid Receptors after Ischemic Stroke. Mediators of Inflammation, 2012(), 708-715-178. https://doi.org/10.1155/2012/824093
Fonseca, B. M., Silva, G. C. D., Almada, M., Costa, M. A., & Teixeira, N. A. (2013). The Endocannabinoid System in the Postimplantation Period: A Role during Decidualization and Placentation. International Journal of Endocrinology, 2013(), 843-853-096. https://doi.org/10.1155/2013/510540
Sardinha, J., Kelly, M. E. M., Zhou, J., & Lehmann, C. (2014). Experimental Cannabinoid 2 Receptor-Mediated Immune Modulation in Sepsis. Mediators of Inflammation, (2014-10), 62-68. https://doi.org/10.1155/2014/978678
Viveros, M. P., Marco, E. M., Llorente, R., & Gallardo, M. L. (2007). Endocannabinoid System and Synaptic Plasticity: Implications for Emotional Responses. Neural Plasticity, 2007(), 393-404. https://doi.org/10.1155/2007/52908

全文下載

主題瀏覽